EUVIMEDEUVIMED entdecken
Open Access

Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival

Pratik Chandra iD, Yi Song iD, Esther Drill iD, Alice C Wei iD, Nancy Kemeny iD, Andrea Cercek iD, Louise Connell iD, James Harding iD, Ghassan Abou-Alfa iD, Wungki Park iD, T Peter Kingham, Kevin Soares iD und 6 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-25-00402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Pratik Chandra und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The impact of first recurrence site on outcome after resection of intrahepatic cholangiocarcinoma (IHC) is ill-defined, as are the genomic underpinnings of recurrence and outcomes. METHODS Resected patients with IHC at two institutions with genomic data were included. Sites of first recurrence (SOFR) were classified as liver only (LO), extrahepatic (EH) only, or simultaneous liver and extrahepatic (SIM). Overall survival (OS) was calculated from the time of recurrence. RESULTS Between 1993 and 2021, 318 patients met inclusion criteria; 232 (73%) recurred. SOFR were LO = 93 (40%), EH = 80 (34%), and SIM = 59 (26%). Median OS from recurrence was similar in the LO (33 [26, 42] months) and EH groups (33 [23, 46] months) but much lower in SIM (12 [9.8, 18] months; P < .001). Moderate/poor tumor differentiation, lymphovascular invasion, N1 disease, perineural invasion, and time to recurrence (all P < .05) were associated with SIM; only positive resection margin predicted LO ( P = .007). No individual genomic or pathway alterations predicted SOFR; however, for all recurrers, TP53 mut (n = 51, 22%; hazard ratio [HR], 2.0 [1.4 to 2.9]; P = .002), CDKN2A del (n = 34, 15%; HR, 3.4 [95% CI, 2.2 to 5.3]; P < .001), CDKN2B (n = 25, 11%; HR, 3.2 [95% CI, 2.0 to 5.0]; P < .001), and KRAS mut (n = 25, 11%; HR, 2.5 [95% CI, 1.6 to 4.0]; P = .002) were associated with worse OS. On multivariable analysis, SIM (HR, 2.5 [95% CI, 1.7 to 3.5]; P < .001), N1 status (HR, 1.8 [95% CI, 1.2 to 2.6]; P = .004), and alterations in the high-risk genotype (TP53 mut , CDKN2A del or KRAS mut ; n = 84, 36%; HR, 2.4 [95% CI, 1.7 to 3.3]; P < .001) were independent predictors of poor OS. CONCLUSION Recurrence after resection of IHC is common, and the liver was the most common site (66%). Clinicopathologic and genomic factors had limited ability to predict SOFR. Although LO and EH were associated with similar OS, SIM recurrences had dramatically worse OS. Adjuvant strategies targeting liver recurrence may improve outcomes after resection of IHC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedGenomicsAgedAdultAged, 80 and over

Autor:innen und Institutionen

  • Department of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Weill Medical School at Cornell University, New York, NY.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Trinity Dublin University, Dublin, Ireland.
  • Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands.

ORCID-Profile: Pratik Chandra, Yi Song, Esther Drill, Alice C Wei, Nancy Kemeny, Andrea Cercek, Louise Connell, James Harding, Ghassan Abou-Alfa, Wungki Park, Kevin Soares, Eileen O'Reilly, Bas Groot Koerkamp, William R Jarnagin

Förderung

  • NCI NIH HHS

Zitieren

APA

Chandra, P., Song, Y., Drill, E., Wei, A. C., Kemeny, N., Cercek, A., Connell, L., Harding, J., Abou-Alfa, G., Park, W., Kingham, T. P., Soares, K., Balachandran, V., Drebin, J., D'Angelica, M., O'Reilly, E., Koerkamp, B. G., & Jarnagin, W. R. (2025). Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival. JCO Precision Oncology. https://doi.org/10.1200/po-25-00402

Vancouver

Chandra P, Song Y, Drill E, Wei AC, Kemeny N, Cercek A, et al. Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival. JCO Precision Oncology. 2025. doi:10.1200/po-25-00402

BibTeX
@article{Chandra2025,
  author = {Chandra, Pratik and Song, Yi and Drill, Esther and Wei, Alice C and Kemeny, Nancy and Cercek, Andrea and Connell, Louise and Harding, James and Abou-Alfa, Ghassan and Park, Wungki and Kingham, T Peter and Soares, Kevin and Balachandran, Vinod and Drebin, Jeffrey and D'Angelica, Michael and O'Reilly, Eileen and Koerkamp, Bas Groot and Jarnagin, William R},
  title = {Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-25-00402}
}
Kostenlos starten →